---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-262591"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T01:01:40.931394+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sarepta reports Q3 GAAP net loss; ESSENCE confirmatory study misses primary endpoint

## Summary
- ESSENCE study did not meet primary endpoint (p=0.309); COVID-adjusted analysis showed trend (p=0.09).
- Net product revenue $370M (PMO $238.5M, ELEVIDYS $131.5M); total revenue $399.4M, down 15% YoY.
- GAAP net loss $179.9M ($1.80 per share) vs net income $33.6M ($0.34) in Q3 2024.
- Refinanced convertible debt to 2030; disposed Arrowhead equity; positive cash flow in Q3.
- ELEVIDYS labeling discussions with FDA nearing conclusion; non-ambulatory indication removal expected.

## SEC filing metadata
- accession: 0001193125-25-262591
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312525262591/0001193125-25-262591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312525262591/srpt-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-262591
- JSON: https://secwatch.observer/filing/0001193125-25-262591.json
- Plain text: https://secwatch.observer/filing/0001193125-25-262591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.